Dr Paloma Giangrande

Scientific Advisory Board

Dr. Paloma Giangrande is an internationally recognized expert in nucleic acid therapeutics and delivery. She pioneered the use of RNA aptamers for targeted siRNA delivery beyond the liver, significantly expanding the therapeutic potential of RNA interference. She has held key leadership roles in renowned biotechnology companies, including as Director of Rare Diseases at Moderna, where she spearheaded mRNA therapeutic programs for rare genetic diseases; as Vice President of Platform Biology at Wave Life Sciences, where she led the groundbreaking RNA Editing program to a first-in-human stage, and as Chief Technology Officer at Eleven Therapeutics, where she drove the strategic direction for the company’s core xRNA technologies and platforms. Her strategic leadership at prestigious institutions underscores her commitment to advancing innovative RNA-based treatments.